Enovis Corp

NYSE ENOV

Download Data

Enovis Corp Sales to Working Capital Ratio 1 year YoY Change (%) for the year ending December 31, 2023: -52.36%

Enovis Corp Sales to Working Capital Ratio 1 year YoY Change (%) is -52.36% for the year ending December 31, 2023, a -141.62% change year over year. The sales to working capital ratio measures the revenue generated by a company relative to its working capital. It is calculated by dividing the revenue by the difference between current assets and current liabilities. This ratio indicates the company's revenue generation efficiency based on its working capital. A higher sales to working capital ratio suggests better utilization of working capital to generate sales revenue. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Enovis Corp Sales to Working Capital Ratio for the year ending December 31, 2022 was 6.80, a 125.81% change year over year.
  • Enovis Corp Sales to Working Capital Ratio for the year ending December 31, 2021 was 3.01, a -46.04% change year over year.
  • Enovis Corp Sales to Working Capital Ratio for the year ending December 31, 2020 was 5.58, a -8.26% change year over year.
  • Enovis Corp Sales to Working Capital Ratio for the year ending December 31, 2019 was 6.08, a 25.95% change year over year.
NYSE: ENOV

Enovis Corp

CEO Mr. Mitchell P. Rales
IPO Date May 8, 2008
Location United States
Headquarters 2711 Centerville Road, Wilmington, DE, United States, 19808
Employees 6,550
Sector Industrials
Industry Specialty industrial machinery
Description

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

Similar companies

HURC

Hurco Companies Inc

NA

NA

IEX

IDEX Corporation

NA

NA

DCI

Donaldson Company Inc

NA

NA

EPAC

Enerpac Tool Group Corp

NA

NA

KAI

Kadant Inc

NA

NA

GHM

Graham Corporation

NA

NA

StockViz Staff

September 19, 2024

Any question? Send us an email